Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab.
Oncology (Williston Park)
; 34(5): 171-174, 2020 May 13.
Article
en En
| MEDLINE
| ID: mdl-32644176
ABSTRACT
A 56-year-old white man with a 74 pack-year smoking history presented with macroscopic hematuria and a significant weight loss of 45 pounds in 6 months. His clinical laboratory tests indicated iron defi ciency anemia and a computed tomography (CT) scan showed a left kidney tumor, mediastinal lymph nodes, and multiple lung metastases. A percutaneous CT-guided kidney biopsy revealed grade 3 clear cell renal carcinoma based on World Health Organization/International Society of Urologic Pathology classifi cation. The patient started first line systemic treatment for intermediate-risk metastatic renal cell carcinoma (mRCC) with combination immunotherapy with nivolumab plus ipilimumab.1 After 10 days of the first cycle, he presented with a pruritic maculopapular rash covering 20% of his body surface.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Renales
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Neoplasias Renales
/
Neoplasias Pulmonares
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2020
Tipo del documento:
Article